Literature DB >> 16320316

Regulation of anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis: contrasting effects of HLA-DR3 and the shared epitope alleles.

Patricia Irigoyen1, Annette T Lee, Mark H Wener, Wentian Li, Marlena Kern, Franak Batliwalla, Raymond F Lum, Elena Massarotti, Michael Weisman, Claire Bombardier, Elaine F Remmers, Daniel L Kastner, Michael F Seldin, Lindsey A Criswell, Peter K Gregersen.   

Abstract

OBJECTIVE: To examine the association between HLA-DRB1 alleles and the production of anti-cyclic citrullinated peptide (anti-CCP) and rheumatoid factor (RF) autoantibodies in patients with rheumatoid arthritis (RA).
METHODS: We studied 1,723 Caucasian RA patients enrolled in the North American Rheumatoid Arthritis Consortium (NARAC) family cohort and the Study of New Onset Rheumatoid Arthritis (SONORA) cohort. All patients were tested for anti-CCP antibodies (by enzyme-linked immunosorbent assay), RF (by nephelometry), and HLA-DR genotype (by polymerase chain reaction and sequence-specific oligonucleotide hybridization).
RESULTS: When controlled for the presence of RF, anti-CCP positivity was strongly associated with the HLA-DRB1 shared epitope (SE). In RF+ patients, the presence of the SE was very significantly associated with anti-CCP positivity, with an odds ratio (OR) of 5.8 and a 95% confidence interval (95% CI) of 4.1-8.3. This relationship was also seen in RF- patients (OR 3.1 [95% CI 1.8-5.3]). In contrast, RF positivity was not significantly associated with presence of the SE independently of anti-CCP antibodies. Strikingly, HLA-DRB1*03 was strongly associated with reduced anti-CCP titers, even after controlling for the presence of the SE and restricting the analysis to anti-CCP+ patients. HLA-DR3 was also associated with anti-CCP- RA in our population.
CONCLUSION: The HLA-DRB1 SE is strongly associated with the production of anti-CCP antibodies, but not RF. In contrast, HLA-DR3 alleles are associated with anti-CCP- disease and with lower levels of anti-CCP antibodies, even when controlling for the SE. These data emphasize the complexity of the genetic effects of the major histocompatibility complex on the RA phenotype.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16320316     DOI: 10.1002/art.21419

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  77 in total

1.  Increased frequency of complement C4B deficiency in rheumatoid arthritis.

Authors:  William F C Rigby; Yee Ling Wu; Moe Zan; Bi Zhou; Sanna Rosengren; Cheryl Carlson; Whitney Hilton; C Yung Yu
Journal:  Arthritis Rheum       Date:  2012-05

Review 2.  Recent advances in the genetics of rheumatoid arthritis.

Authors:  Chris Deighton; Lindsey A Criswell
Journal:  Curr Rheumatol Rep       Date:  2006-10       Impact factor: 4.592

3.  Two independent alleles at 6q23 associated with risk of rheumatoid arthritis.

Authors:  Robert M Plenge; Chris Cotsapas; Leela Davies; Alkes L Price; Paul I W de Bakker; Julian Maller; Itsik Pe'er; Noel P Burtt; Brendan Blumenstiel; Matt DeFelice; Melissa Parkin; Rachel Barry; Wendy Winslow; Claire Healy; Robert R Graham; Benjamin M Neale; Elena Izmailova; Ronenn Roubenoff; Alexander N Parker; Roberta Glass; Elizabeth W Karlson; Nancy Maher; David A Hafler; David M Lee; Michael F Seldin; Elaine F Remmers; Annette T Lee; Leonid Padyukov; Lars Alfredsson; Jonathan Coblyn; Michael E Weinblatt; Stacey B Gabriel; Shaun Purcell; Lars Klareskog; Peter K Gregersen; Nancy A Shadick; Mark J Daly; David Altshuler
Journal:  Nat Genet       Date:  2007-11-04       Impact factor: 38.330

Review 4.  Antibodies to citrullinated proteins: pathogenic and diagnostic significance.

Authors:  V Michael Holers
Journal:  Curr Rheumatol Rep       Date:  2007-10       Impact factor: 4.592

5.  Anticyclic citrullinated peptide antibody-negative rheumatoid arthritis: clues to disease pathogenesis.

Authors:  Mary K Crow
Journal:  Curr Rheumatol Rep       Date:  2008-07       Impact factor: 4.592

Review 6.  Genetic markers as therapeutic target in rheumatoid arthritis: A game changer in clinical therapy?

Authors:  A M Mohamed Thoufic Ali; S Vino
Journal:  Rheumatol Int       Date:  2016-09-16       Impact factor: 2.631

Review 7.  Anti-citrullinated peptide antibodies and their value for predicting responses to biologic agents: a review.

Authors:  Emilio Martin-Mola; Alejandro Balsa; Rosario García-Vicuna; Juan Gómez-Reino; Miguel Angel González-Gay; Raimon Sanmartí; Estíbaliz Loza
Journal:  Rheumatol Int       Date:  2016-06-06       Impact factor: 2.631

8.  [Genetics of rheumatoid arthritis].

Authors:  U Wagner
Journal:  Z Rheumatol       Date:  2011-04       Impact factor: 1.372

Review 9.  Rheumatoid arthritis genetics: 2009 update.

Authors:  Robert M Plenge
Journal:  Curr Rheumatol Rep       Date:  2009-10       Impact factor: 4.592

Review 10.  Rheumatoid arthritis: a view of the current genetic landscape.

Authors:  M J H Coenen; P K Gregersen
Journal:  Genes Immun       Date:  2008-11-06       Impact factor: 2.676

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.